We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+63.27%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$696M
AUM Growth
+$331M
Cap. Flow
+$86M
Cap. Flow %
12.35%
Top 10 Hldgs %
99.82%
Holding
12
New
3
Increased
–
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
APRE icon
Aprea Therapeutics
APRE
+$60.8M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$34.6M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$7.19M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$14.2M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$1.32M
3
ADVM
Adverum Biotechnologies
ADVM
+$1.14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$307M 44.16%
4,183,064
-22,551
-0.5% -$1.32M
ADVM
2
DELISTED
Adverum Biotechnologies
ADVM
$146M 21.01%
700,389
-6,434
-0.9% -$1.14M
APRE icon
3
Aprea Therapeutics
APRE
$7.6M
$71.9M 10.33%
+92,711
New +$60.8M
AKRO
4
DELISTED
Akero Therapeutics
AKRO
$52.7M 7.57%
2,115,454
-621,118
-23% -$14.2M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.88B
$35.6M 5.11%
+2,030,616
New +$34.6M
VCYT icon
6
Veracyte
VCYT
$4.44B
$31.2M 4.49%
1,205,407
– –
GRTS
7
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$20.6M 2.96%
3,102,929
– –
OCUL icon
8
Ocular Therapeutix
OCUL
$1.85B
$18.5M 2.65%
2,215,384
– –
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.8M 1.26%
+1,724,909
New +$7.19M
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
$1.9M 0.27%
543,753
– –
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$688K 0.1%
101,855
– –
VANI icon
12
Vivani Medical
VANI
$113M
$550K 0.08%
187,204
– –

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q2 2020 Portfolio in Review

As of Q2 2020, Versant Venture Management held 12 positions worth $696M, up 91% from $365M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $86M of net new capital in Q2 2020, opening 3 new positions. Its largest new stake was Aprea Therapeutics: 92,711 shares worth $71.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Akero Therapeutics, an estimated $14.2M trimmed.

  • Versant Venture Management's largest Q2 2020 buy was Aprea Therapeutics: 92,711 shares worth $71.9M.
  • Versant Venture Management's biggest Q2 2020 reduction was Akero Therapeutics, cutting an estimated $14.2M.
  • Versant Venture Management's ten largest holdings make up 100% of its $696M portfolio in Q2 2020.
  • Versant Venture Management opened 3 new positions and closed 0 in Q2 2020.
  • Versant Venture Management's portfolio value rose 91% quarter-over-quarter to $696M.

Based on Versant Venture Management's 13F filing for Q2 2020, filed 20 Jul 2020.